Loading...
Loading...
Generating destination analysis
Market Cap
$200B
P/E
32
Revenue Growth
+4.0%
Gross Margin
N/A
ROE
N/A
Thermo Fisher Scientific is a mega-cap healthcare company listed on the NYSE, blending biotech and genomics initiatives alongside its core business operations. Life sciences tools giant providing instruments, reagents, and services to biotech. Valued at 32x trailing earnings with a $200B market capitalization, Thermo Fisher Scientific has delivered modest revenue growth with revenue moving +4% over the past year.
Expert analysis and coverage for Thermo Fisher Scientific
Or unlock everything now with Compass, $9/moPrice vs 200DMA
DMA Convergence
50 DMA
200 DMA
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Recursion Pharmaceuticals
AI-driven drug discovery platform using machine learning to decode biology at scale.